Subscribe To

Price Alert Latest News Economic Calendar News

HUM / For Fourth Consecutive Year, CarePlus Health Plans Attains Medicare's Highest 5 out of 5-Star Rating for 2022

MIAMI--(BUSINESS WIRE)--It's the fifth time and fourth consecutive year that CarePlus Health Plans, Inc.'s Medicare Advantage HMO plan in Florida has achieved the highest possible quality rating, 5 out of 5 stars, from the Centers for Medicare & Medicaid Services (CMS). CarePlus is a subsidiary of Humana Inc. (NYSE: HUM). The 5-star rating recognizes the continued emphasis the company has placed on creating the highest possible quality healthcare and customer service experience for its memb Read More

Demo Live Account See Partner Details

Content Topics

Fourth

Consecutive

Year

Careplus

Health

Plans

Attains

Medicare s

Highest

5 star

Rating

Stock

HUM

Posted: Oct 8 2021, 15:17

Author Name: Business Wire

HUM News

By Zacks Investment Research
November 2, 2023

Here's Why Humana (HUM) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

By Zacks Investment Research
November 1, 2023

Humana (HUM) Q3 Earnings Beat on Strong Individual MA Unit

Humana (HUM) continues to project 2023 adjusted EPS at a minimum of $28.25, which suggests growth from the 2022 figure of $25.88.

By Zacks Investment Research
November 1, 2023

Humana (HUM) Q3 Earnings and Revenues Beat Estimates

Humana (HUM) came out with quarterly earnings of $7.78 per share, beating the Zacks Consensus Estimate of $7.15 per share. This compares to earnings o

By Market Watch
November 1, 2023

Humana Q3 net income, revenue beats analyst estimate

Humana Inc.'s stock HUM rose 0.3% in premarket trading on Wednesday after the health insurance company's third-quarter net income and revenue beat ana

By Reuters
November 1, 2023

Humana beats quarterly profit estimates

Humana Inc on Wednesday beat Wall Street estimates for quarterly profit aided by a better-than-expected performance of its government-backed insurance

By Zacks Investment Research
October 27, 2023

Will Lower CenterWell Profit Hurt Humana's (HUM) Q3 Earnings?

Humana's (HUM) third-quarter results are likely to reflect higher investment income and premiums.

By Zacks Investment Research
October 23, 2023

Humana (HUM) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Humana (HUM) concluded the recent trading session at $515.48, signifying a -1.09% move from its prior day's close.

By Zacks Investment Research
October 17, 2023

Humana (HUM) Registers a Bigger Fall Than the Market: Important Facts to Note

The latest trading day saw Humana (HUM) settling at $519.87, representing a -0.83% change from its previous close.

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.